Last updated: May 25, 2026
Suppliers for DEXMETHYLPHENIDATE HYDROCHLORIDE: API and Finished-Dose Manufacturing Sources by Supply Chain Node
Dexmethylphenidate hydrochloride supply is concentrated in a small set of organizations covering (1) API manufacture, (2) proprietary finished-dose production for branded products, and (3) generic finished-dose manufacturing under FDA-approved ANDAs. The most material “supplier” in practice for a buyer is the API manufacturer and any contract manufacturer that holds the capability to make the specific dosage form (IR/ER; bead/OSMOTIC/MR platform varies by product).
Fast read (what matters for procurement and IP diligence)
- API sourcing: Typically limited; confirm whether a candidate supplier is a true dexmethylphenidate HCl API producer versus a repacker or distributor.
- Finished dose sourcing: Buyers usually rely on FDA-approved finished-dose manufacturers (internal brand supply for branded labels; contract and generic manufacturers for ANDAs).
- Regulatory linkage: Only facilities with an FDA inspection history that supports the specific ANDA/label are credible for compliance-led procurement.
- Patent/IP: For many dexmethylphenidate products, formulation and process patents can constrain contract manufacturing of equivalent product unless the manufacturer is already producing the approved generic/authorized version.
Which companies supply dexmethylphenidate hydrochloride API?
Featured snippet answer: API supply is dominated by a small number of specialized chemical manufacturers capable of producing dexmethylphenidate hydrochloride at pharmaceutical grade, typically with DEA scheduling compliance and cGMP documentation. Finished-dose procurement is commonly routed through ANDA or contract manufacturers rather than direct API procurement.
How to identify true dexmethylphenidate HCl API suppliers
For commercial diligence, classify candidates into three buckets:
- API manufacturer (cGMP): Manufactures dexmethylphenidate hydrochloride API under GMP and supports DMF/Letter of Authorization linkage to ANDAs.
- Intermediate producer: Produces key intermediates (not end API). Useful for backward integration but not a direct “API supplier” for procurement.
- Distributor/repacker: Markets API without manufacturing. Often fails compliance requirements if buyers need facility traceability for regulatory submissions.
Typical API supply chain constraints for dexmethylphenidate
- Controlled substance handling: Dexmethylphenidate is regulated as part of the broader methylphenidate class; suppliers must support DEA and state-controlled distribution workflows.
- Specific cGMP controls: Impurity profile, chiral purity, and residual solvents matter.
- Platform compatibility: ER formulations can impose tighter constraints on API quality specs (particle size, stability, and assay margins).
Who manufactures dexmethylphenidate hydrochloride finished doses (IR vs ER)?
Featured snippet answer: Branded and many generic products for dexmethylphenidate are produced by finished-dose manufacturers that hold ANDA approvals and produce the specific release platform on approved labels (IR vs ER). “Suppliers” in the finished-dose sense are the NDA/ANDA manufacturing sites that produce tablets/capsules under cGMP.
Key finished-dose categories buyers sort
- Immediate-release (IR): Shorter duration; formulation and manufacturing controls differ from ER.
- Extended-release (ER): Delivery platform matters (bead technology, osmotic systems, or other sustained-release designs). API particle and blend behavior can be formulation-sensitive.
Manufacturing site mapping approach
For procurement and regulatory readiness, buyers map suppliers to:
- The ANDA label’s listed manufacturer(s) and manufacturing/packaging sites
- NDA/ANDA site inspection status
- The specific strength and dosage form (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 25 mg, etc., varies by product)
What are the main ANDA/generic supply sources for dexmethylphenidate HCl?
Featured snippet answer: Generic dexmethylphenidate hydrochloride finished doses are supplied by ANDA holders and their contract manufacturers, with product-level manufacturing tied to FDA-approved sites.
Procurement-relevant supplier signals
When selecting generic suppliers, buyers typically prioritize:
- ANDA holder identity (marketing rights) versus the contract manufacturer (production)
- Manufacturing location listed for the finished dose
- Evidence of consistent supply history and ability to scale production during shortages
How do “API suppliers” compare with “finished-dose manufacturers” for dexmethylphenidate?
Featured snippet answer: API suppliers feed contract and finished-dose manufacturers. For most buyers, the procurement unit that impacts compliance is the finished-dose cGMP manufacturer tied to FDA approvals.
Comparison table: roles and diligence focus
| Supply node |
What it supplies |
Buyer diligence focus |
Typical documentation needed |
| API manufacturer |
Dexmethylphenidate HCl API |
DMF linkage, cGMP compliance, impurity/chiral specs |
DMF/LOA references, CoA specs, GMP certificates |
| Intermediate producer |
Key chemical intermediate |
Ability to supply consistent input and quality control |
Intermediate CoA, process controls, change history |
| Finished-dose manufacturer (ANDA/NDA) |
IR/ER tablets/capsules |
Site-level inspection readiness; platform-specific compatibility |
ANDA label site list, batch records summaries, validation package summaries |
| Distributor |
Physical API movement |
Traceability and controlled-substance distribution compliance |
Chain-of-custody, licenses, lot traceability |
What licensing and supply deals exist for dexmethylphenidate hydrochloride?
Featured snippet answer: Supply arrangements for dexmethylphenidate products are usually embedded in NDA/ANDA licensing structures, where ANDA holders use contract manufacturers and brands rely on internal or contracted production.
What buyers should look for in supply/technology licensing
- Platform technology licensing for ER (release mechanism specific)
- Patent-expiration and “authorized generic” strategy
- Supply exclusivity clauses tied to launch readiness and post-approval commitments
What patent/IP constraints affect who can supply dexmethylphenidate?
Featured snippet answer: Patent estates can restrict manufacture of specific ER platforms and formulation/process variants, affecting which contract manufacturers are willing or able to supply equivalent products for branded or generic channels.
Patent diligence lens (practical)
- Formulation patents: binder matrix, release-modifier system, coating or bead structure
- Process patents: synthesis route and impurity-control methods
- Method-of-use patents: less common as a manufacturing constraint but relevant for label-level challenges
Key regulatory sourcing gate: FDA status of supplier manufacturing sites
Featured snippet answer: For finished-dose supply, the credible supplier is the FDA-approved manufacturing site associated with the product’s ANDA/NDA label.
Regulatory gating points in supplier selection
- Facility inspection history for the relevant dosage form
- Ability to produce at the labeled strengths with validated scale-up
- Compliance with controlled-substance handling and recordkeeping
Key takeaways
- Dexmethylphenidate hydrochloride supply is split between API manufacturing and finished-dose cGMP production tied to FDA approvals.
- The most actionable “supplier” for procurement is the finished-dose manufacturer site listed for the specific IR/ER product, not a generic distributor of API.
- Supplier selection should align with dosage form platform, controlled-substance logistics, and FDA site compliance.
- IP and formulation/process constraints can limit contract manufacturing participation for equivalent ER designs.
FAQs
- How do I determine whether a company truly manufactures dexmethylphenidate HCl API versus resells it?
- Which documentation links an ANDA product to the specific API DMF and manufacturer for dexmethylphenidate?
- What changes in API quality (chiral purity, impurities) most affect dexmethylphenidate ER formulations?
- What manufacturing site information matters most when selecting an ANDA supplier for dexmethylphenidate tablets/capsules?
- How do controlled-substance compliance requirements affect dexmethylphenidate supply continuity?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- U.S. Drug Enforcement Administration. Controlled Substances schedules and registration requirements. (Accessed 2026).
- FDA. Drug Master Files (DMF): Industry information. (Accessed 2026).
